449 related articles for article (PubMed ID: 21485024)
1. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.
Pincus T; Furer V; Keystone E; Yazici Y; Bergman MJ; Luijtens K
Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1142-9. PubMed ID: 21485024
[TBL] [Abstract][Full Text] [Related]
2. Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trials.
Pincus T; Hines P; Bergman MJ; Yazici Y; Rosenblatt LC; MacLean R
J Rheumatol; 2011 Dec; 38(12):2565-71. PubMed ID: 22089467
[TBL] [Abstract][Full Text] [Related]
3. Can RAPID3, an index without formal joint counts or laboratory tests, serve to guide rheumatologists in tight control of rheumatoid arthritis in usual clinical care?
Pincus T
Bull NYU Hosp Jt Dis; 2009; 67(3):254-66. PubMed ID: 19852747
[TBL] [Abstract][Full Text] [Related]
4. Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort.
Castrejón I; Dougados M; Combe B; Guillemin F; Fautrel B; Pincus T
J Rheumatol; 2013 Apr; 40(4):386-93. PubMed ID: 23378463
[TBL] [Abstract][Full Text] [Related]
5. RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds.
Pincus T; Swearingen CJ; Bergman MJ; Colglazier CL; Kaell AT; Kunath AM; Siegel EL; Yazici Y
Arthritis Care Res (Hoboken); 2010 Feb; 62(2):181-9. PubMed ID: 20191516
[TBL] [Abstract][Full Text] [Related]
6. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories.
Pincus T; Swearingen CJ; Bergman M; Yazici Y
J Rheumatol; 2008 Nov; 35(11):2136-47. PubMed ID: 18793006
[TBL] [Abstract][Full Text] [Related]
7. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care.
Pincus T; Yazici Y; Bergman MJ
Rheum Dis Clin North Am; 2009 Nov; 35(4):773-8, viii. PubMed ID: 19962621
[TBL] [Abstract][Full Text] [Related]
8. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures.
Pincus T; Bergman MJ; Yazici Y; Hines P; Raghupathi K; Maclean R
Rheumatology (Oxford); 2008 Mar; 47(3):345-9. PubMed ID: 18238788
[TBL] [Abstract][Full Text] [Related]
9. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial.
Smolen JS; Emery P; Ferraccioli GF; Samborski W; Berenbaum F; Davies OR; Koetse W; Purcaru O; Bennett B; Burkhardt H
Ann Rheum Dis; 2015 May; 74(5):843-50. PubMed ID: 24431394
[TBL] [Abstract][Full Text] [Related]
10. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial.
Keystone EC; Combe B; Smolen J; Strand V; Goel N; van Vollenhoven R; Mease P; Landewé R; Fleischmann R; Luijtens K; van der Heijde D
Rheumatology (Oxford); 2012 Sep; 51(9):1628-38. PubMed ID: 22596211
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data.
Curtis JR; Chen L; Luijtens K; Navarro-Millan I; Goel N; Gervitz L; Weinblatt M
Arthritis Rheum; 2011 Aug; 63(8):2203-8. PubMed ID: 21484766
[TBL] [Abstract][Full Text] [Related]
12. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.
Connock M; Tubeuf S; Malottki K; Uthman A; Round J; Bayliss S; Meads C; Moore D
Health Technol Assess; 2010 Oct; 14(Suppl. 2):1-10. PubMed ID: 21047485
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience.
Singh H; Gupta V; Ray S; Kumar H; Talapatra P; Kaur M; Kumar S; Arya S; Mathur R; Ghangas N
Clin Rheumatol; 2012 Dec; 31(12):1663-9. PubMed ID: 22983768
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
Mod Rheumatol; 2014 Sep; 24(5):715-24. PubMed ID: 24313916
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol.
Curtis JR; Churchill M; Kivitz A; Samad A; Gauer L; Gervitz L; Koetse W; Melin J; Yazici Y
Arthritis Rheumatol; 2015 Dec; 67(12):3104-12. PubMed ID: 26316013
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
Keystone E; Landewé R; van Vollenhoven R; Combe B; Strand V; Mease P; Shaughnessy L; VanLunen B; van der Heijde D
Ann Rheum Dis; 2014 Dec; 73(12):2094-100. PubMed ID: 23918037
[TBL] [Abstract][Full Text] [Related]
17. Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial.
Keystone EC; Curtis JR; Fleischmann RM; Furst DE; Khanna D; Smolen JS; Mease PJ; Schiff MH; Coteur G; Davies O; Combe B
J Rheumatol; 2011 Jun; 38(6):990-6. PubMed ID: 21362764
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Iwai K; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
Mod Rheumatol; 2014 Jul; 24(4):552-60. PubMed ID: 24981319
[TBL] [Abstract][Full Text] [Related]
19. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
Wechalekar MD; Lester S; Proudman SM; Cleland LG; Whittle SL; Rischmueller M; Hill CL
Arthritis Rheum; 2012 May; 64(5):1316-22. PubMed ID: 22135142
[TBL] [Abstract][Full Text] [Related]
20. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial.
van der Heijde D; Keystone EC; Curtis JR; Landewé RB; Schiff MH; Khanna D; Kvien TK; Ionescu L; Gervitz LM; Davies OR; Luijtens K; Furst DE
J Rheumatol; 2012 Jul; 39(7):1326-33. PubMed ID: 22589265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
